Compare SLE & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLE | NGEN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Canada |
| Employees | 34 | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 200.0M |
| IPO Year | 2019 | 2018 |
| Metric | SLE | NGEN |
|---|---|---|
| Price | $3.86 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $60.00 | $18.00 |
| AVG Volume (30 Days) | ★ 1.9M | 457.8K |
| Earning Date | 05-14-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,064,000.00 | N/A |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $49.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.48 | $1.58 |
| 52 Week High | $11.43 | $5.93 |
| Indicator | SLE | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 80.28 |
| Support Level | $2.89 | $1.62 |
| Resistance Level | $4.89 | $4.44 |
| Average True Range (ATR) | 0.83 | 0.12 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 33.52 | 92.21 |
Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.